[go: up one dir, main page]

CN114394962A - A kind of preparation method of N-desmethylzolmitriptan - Google Patents

A kind of preparation method of N-desmethylzolmitriptan Download PDF

Info

Publication number
CN114394962A
CN114394962A CN202111582833.XA CN202111582833A CN114394962A CN 114394962 A CN114394962 A CN 114394962A CN 202111582833 A CN202111582833 A CN 202111582833A CN 114394962 A CN114394962 A CN 114394962A
Authority
CN
China
Prior art keywords
preparation
desmethylzolmitriptan
compound
present
demethylzolmitriptan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202111582833.XA
Other languages
Chinese (zh)
Inventor
沈歆悦
李方林
王志强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Xianggen Biomedical Co ltd
Original Assignee
Shenzhen Xianggen Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Xianggen Biomedical Co ltd filed Critical Shenzhen Xianggen Biomedical Co ltd
Priority to CN202111582833.XA priority Critical patent/CN114394962A/en
Publication of CN114394962A publication Critical patent/CN114394962A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a preparation method of N-demethyl zolmitriptan, which is characterized in that the N-demethyl zolmitriptan is obtained by the reaction of zolmitriptan and demethylating reagent.

Description

一种N-去甲基佐米曲普坦的制备方法A kind of preparation method of N-desmethylzolmitriptan

技术领域technical field

本发明属于药物合成技术领域,涉及一种N-去甲基佐米曲普坦的制备方法。The invention belongs to the technical field of drug synthesis, and relates to a preparation method of N-desmethylzolmitriptan.

背景技术Background technique

佐米曲普坦,化学名为(S)-4-[3-[2-(二甲胺基)乙基]-1H-吲哚-5-甲基]-2-噁唑烷酮,是由德国Glaxo-Wellcome公司开发的抗偏头痛药物,它是一种选择性很强的5-羟色胺(5-TH1B和5-TH1D)受体激动剂,通过激动颅内血管(包括动静脉吻合处)和三叉神经系统交感神经上的5-HTIB/ID受体,收缩血管和抑制神经肽的释放缓解偏头痛的发作。目前已在英国、美国等国上市,市场前景良好。Zolmitriptan, chemical name (S)-4-[3-[2-(dimethylamino)ethyl]-1H-indole-5-methyl]-2-oxazolidinone, is An anti-migraine drug developed by Glaxo-Wellcome in Germany, it is a highly selective serotonin (5-TH1B and 5-TH1D) receptor agonist, which stimulates intracranial blood vessels (including arteriovenous anastomosis) ) and 5-HTIB/ID receptors on the sympathetic nerves of the trigeminal nervous system, constrict blood vessels and inhibit the release of neuropeptides to relieve migraine attacks. At present, it has been listed in the United Kingdom, the United States and other countries, and the market prospect is good.

根据公开信息报道,佐米曲普坦主要经肝脏代谢为吲哚乙酸、N-氧化物及N-去甲基佐米曲普坦,其中吲哚乙酸和N-氧化物在体内没有活性,而N-去甲基代谢物是5-羟色胺1D激动剂,活性是佐米曲普坦的2-6倍。因此为了保障佐米曲普坦的合理用药及生态环境安全,对N-去甲基佐米曲普坦进行深入的研究具有重要意义。本发明公开的N-去甲基佐米曲普坦的制备方法,可为佐必克隆的研究提供重要的支持。本发明提供的N-去甲基佐米曲普坦的制备方法,目前尚未有文献报道。According to public information reports, zolmitriptan is mainly metabolized by the liver to indole acetic acid, N-oxide and N-desmethylzolmitriptan, of which indole acetic acid and N-oxide are inactive in the body, while The N-desmethyl metabolite is a serotonin 1D agonist with 2-6 times the activity of zolmitriptan. Therefore, in order to ensure the rational use of zolmitriptan and the safety of the ecological environment, it is of great significance to conduct in-depth research on N-desmethylzolmitriptan. The preparation method of N-desmethylzolmitriptan disclosed in the invention can provide important support for the research of zobiclone. The preparation method of N-desmethylzolmitriptan provided by the present invention has not yet been reported in the literature.

发明内容SUMMARY OF THE INVENTION

发明目的:针对上述现有技术,本申请提供了一种N-去甲基佐米曲普坦的制备方法。Object of the invention: In view of the above prior art, the present application provides a preparation method of N-desmethylzolmitriptan.

技术方案:为实现以上目的,本发明采用以下方案:Technical scheme: in order to realize the above purpose, the present invention adopts the following scheme:

一种式ⅡN-去甲基佐米曲普的制备方法,所述制备方法包括将化合物Ⅰ在有机溶剂中与脱甲基试剂反应,得到化合物Ⅱ;其合成路线如下:A preparation method of formula IIN-desmethylzolmitrip, the preparation method comprises reacting compound I with a demethylation reagent in an organic solvent to obtain compound II; the synthetic route thereof is as follows:

Figure 477760DEST_PATH_IMAGE001
Figure 477760DEST_PATH_IMAGE001
.

在本发明的实施方案中,本发明提供的一种N-去甲基佐米曲普坦的制备方法,所述的有机溶剂为丙酮或者丁酮。In an embodiment of the present invention, the present invention provides a method for preparing N-desmethylzolmitriptan, wherein the organic solvent is acetone or butanone.

在本发明的实施方案中,本发明提供的N-去甲基佐米曲普坦的制备方法,所述化合物Ⅰ与有机溶剂的质量体积比(g/ml)为1:5-15。In an embodiment of the present invention, in the preparation method of N-desmethylzolmitriptan provided by the present invention, the mass-volume ratio (g/ml) of the compound I to the organic solvent is 1:5-15.

在本发明的实施方案中,本发明提供的N-去甲基佐米曲普坦的制备方法,所述的脱甲基试剂为偶氮二甲酸二乙酯、偶氮二甲酸二异丙酯或者偶氮二甲酸二叔丁酯。In an embodiment of the present invention, in the preparation method of N-desmethylzolmitriptan provided by the present invention, the demethylation reagents are diethyl azodicarboxylate and diisopropyl azodicarboxylate Or di-tert-butyl azodicarboxylate.

在本发明的实施方案中,本发明提供的一种式N-去甲基佐米曲普坦的制备方法,所述化合物Ⅰ与脱甲基试剂的反应摩尔比为1:1.5-5。In an embodiment of the present invention, the present invention provides a preparation method of N-desmethylzolmitriptan, wherein the reaction molar ratio of the compound I and the demethylation reagent is 1:1.5-5.

在本发明的实施方案中,本发明提供的一种N-去甲基佐米曲普坦的制备方法,所述反应的反应温度为0-50℃。In an embodiment of the present invention, the present invention provides a method for preparing N-desmethylzolmitriptan, wherein the reaction temperature of the reaction is 0-50°C.

在本发明的实施方案中,本发明提供的一种N-去甲基佐米曲普坦的制备方法,所述反应的反应时间为6-24h。In an embodiment of the present invention, the present invention provides a preparation method of N-desmethylzolmitriptan, and the reaction time of the reaction is 6-24h.

本发明的有益结果在于:The beneficial results of the present invention are:

本发明提供了式(Ⅱ)所示N-去甲基佐米曲普坦的制备方法,所述方法一步化学反应步骤即可得到目标产物,分离步骤简单,便于操作,可快速制备N-去甲基佐米曲普坦,可用于药代动力学、原料药杂质鉴定、环境控制和保护等研究,为佐米曲普坦的杂质鉴定、代谢机理、新药研究设计、环境保护等,具有重要的应用价值。The invention provides a preparation method of N-desmethylzolmitriptan represented by formula (II). The method can obtain the target product in one chemical reaction step, the separation steps are simple, the operation is convenient, and the N-desmethylzolmitriptan can be quickly prepared. Methylzolmitriptan can be used for studies on pharmacokinetics, raw material impurity identification, environmental control and protection. application value.

具体实施方式Detailed ways

实施例1Example 1

500ml三口瓶中,加入化合物Ⅰ(14.3g, 50mmol)和丙酮(70ml),然后氮气交换三次,接着缓慢加入偶氮二甲酸二乙酯(26.1g, 75mmol),室温反应12h,反应液浓缩,残留物经柱色谱纯化得化合物Ⅱ。In a 500ml three-necked flask, add compound I (14.3g, 50mmol) and acetone (70ml), then nitrogen exchange three times, then slowly add diethyl azodicarboxylate (26.1g, 75mmol), react at room temperature for 12h, the reaction solution is concentrated, The residue was purified by column chromatography to obtain compound II.

实施例2Example 2

500ml三口瓶中,加入化合物Ⅰ(14.3g, 50mmol)和丁酮(215ml),然后氮气交换三次,接着缓慢加入偶氮二甲酸二叔丁酯(34.5g, 150mmol),50℃反应6h,反应液浓缩,残留物经柱色谱纯化得化合物Ⅱ。In a 500ml three-necked flask, add compound I (14.3g, 50mmol) and butanone (215ml), then nitrogen exchange three times, then slowly add di-tert-butyl azodicarboxylate (34.5g, 150mmol), react at 50°C for 6h, the reaction The liquid was concentrated, and the residue was purified by column chromatography to obtain compound II.

实施例3Example 3

500ml三口瓶中,加入化合物Ⅰ(14.3g, 50mmol)和丙酮(180ml),然后氮气交换三次,接着缓慢加入偶氮二甲酸二叔甲酯(36.5g, 250mmol),0℃反应24h,反应液浓缩,残留物经柱色谱纯化得化合物Ⅱ。In a 500ml three-necked flask, add compound I (14.3g, 50mmol) and acetone (180ml), then nitrogen exchange three times, then slowly add di-tert-methyl azodicarboxylate (36.5g, 250mmol), react at 0°C for 24h, the reaction solution After concentration, the residue was purified by column chromatography to obtain compound II.

1H NMR (400MHz, DMSO-d 6 ) δ: 7.37(s, 1H), 7.27(d , 1H), 7.10(s, 1H),6.94(d, 1H), 4.21-4.25 (m, 1H), 4.00-4.08 (m, 2H), 2.75-287 (m, 6H), 2.35 (s,3H)。 1 H NMR (400MHz, DMSO- d 6 ) δ: 7.37 (s, 1H), 7.27 (d, 1H), 7.10 (s, 1H), 6.94 (d, 1H), 4.21-4.25 (m, 1H), 4.00-4.08 (m, 2H), 2.75-287 (m, 6H), 2.35 (s, 3H).

以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。The above are only the preferred embodiments of the present invention. It should be pointed out that for those skilled in the art, without departing from the principles of the present invention, several improvements and modifications can be made. It should be regarded as the protection scope of the present invention.

Claims (7)

1. A preparation method of N-demethyl zolmitriptan is characterized in that the preparation method comprises the steps of reacting a compound I with a demethylation reagent in an organic solvent to obtain a compound II; the reaction route is as follows:
Figure 967541DEST_PATH_IMAGE001
2. the method for preparing N-demethylzolmitriptan as claimed in claim 1, wherein the organic solvent is acetone or butanone.
3. The preparation method of N-demethylzolmitriptan as claimed in claim 1, wherein the mass-to-volume ratio (g/ml) of the compound I to the organic solvent is 1: 5-15.
4. The process of claim 1, wherein the demethylating agent is diethyl azodicarboxylate, diisopropyl azodicarboxylate or di-tert-butyl azodicarboxylate.
5. The process for preparing N-demethylzolmitriptan as claimed in claim 1, wherein the molar ratio of compound i to demethylating agent is 1: 1.5-5.
6. The process for preparing N-demethylzolmitriptan as claimed in claim 1, wherein the reaction temperature is 0-50 ℃.
7. The method for preparing N-demethylzolmitriptan as claimed in claim 1, wherein the reaction time is 6-24 h.
CN202111582833.XA 2021-12-22 2021-12-22 A kind of preparation method of N-desmethylzolmitriptan Withdrawn CN114394962A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111582833.XA CN114394962A (en) 2021-12-22 2021-12-22 A kind of preparation method of N-desmethylzolmitriptan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111582833.XA CN114394962A (en) 2021-12-22 2021-12-22 A kind of preparation method of N-desmethylzolmitriptan

Publications (1)

Publication Number Publication Date
CN114394962A true CN114394962A (en) 2022-04-26

Family

ID=81227248

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111582833.XA Withdrawn CN114394962A (en) 2021-12-22 2021-12-22 A kind of preparation method of N-desmethylzolmitriptan

Country Status (1)

Country Link
CN (1) CN114394962A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018897A1 (en) * 1990-06-07 1991-12-12 The Wellcome Foundation Limited Therapeutic heterocyclic compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991018897A1 (en) * 1990-06-07 1991-12-12 The Wellcome Foundation Limited Therapeutic heterocyclic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EDWARD E.SMISSMAN, ET AL.: "Azodicarboxylic Acid Esters as Dealkylating Agents", 《J. ORG. CHEM., 》, vol. 38, no. 9, 31 December 1973 (1973-12-31), pages 1652 - 1657 *
VASANTHA MITTAPELLI, ET AL.: "N-Desmethyltriptans: One pot efficient synthesis of N-methyl-2-[5-[substituted-1Hindole- 3-yl]ethanamines", 《INDIAN JOURNAL OF CHEMISTRY》, vol. 48, 30 April 2009 (2009-04-30), pages 590 - 594 *

Similar Documents

Publication Publication Date Title
JPS5943459B2 (en) N-alkylpiperidine derivative
CN102229613B (en) New process for synthesis of asenapine
CN112062767B (en) Preparation method and intermediate of rumepilone
CN103601645B (en) The preparation method of 1-(phenethyl amino) propane-2-alcohol compound or its salt
CN118598813B (en) L-malic acid salsa Mi Duofen and preparation method thereof
CN114394962A (en) A kind of preparation method of N-desmethylzolmitriptan
EP3081554B1 (en) Method for preparing silodosin and intermediate thereof
WO2011091677A1 (en) Preparation method of aliskiren intermediate 3-amino-2,2-dimethyl propanamide
US6870070B2 (en) Process to prepare 2-aminoindan derivatives
CN114315609B (en) Technological method for preparing cis-2-aminocyclohexanol
CN112552184B (en) Synthetic method of cyclopropyl-containing chiral amine hydrochloride
WO2014008639A1 (en) Method for preparing indacaterol
WO2021259051A1 (en) Method for improving synthesis process of hypidone free base
CN101514167A (en) Preparation method of chiral baclofen
CN110885315A (en) Preparation method of important intermediate of levosimendan
CN113527108B (en) Process for preparing optically pure 5, 7-difluoro-1, 2,3, 4-tetrahydronaphthalen-2-amine and salts thereof
CN115477635B (en) A preparation method of lasmiditan
KR101686087B1 (en) Process for Production of Optically Active Indoline Derivatives or Salts Thereof
CN112321451B (en) Method for preparing cinacalcet hydrochloride drug intermediate
CN111960962B (en) A nickel-catalyzed α-alkylation method of acetamide and thioacetamide
CN113493385B (en) Method for synthesizing butenafine hydrochloride
CN113149891B (en) Preparation method of 2-amino-2- (1-methyl-4-piperidinyl) ethanol
CN104817451B (en) The preparation method of p-methoxyphenylacetic acid
CN114292199A (en) A kind of preparation method of tramadol hydrochloride impurity C
CN117820257A (en) Preparation method of pinaverium bromide intermediate with high cis-isomer content

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20220426